The purpose of this study was to investigate the effect of morin, a flavonoid, on the pharmacokinetics of diltiazem and one of its metabolites, desacetyldiltiazem in rats. Pharmacokinetic parameters of diltiazem and desacetyldiltiazem were determined after oral administration of diltiazem (15 mglkg) in rats pretreated with morin (1.5, 7.5, and 15 mg/kg). Compared with the control group (given diltiazem alone), pretreatment of morin significantly increased the absorption rate constant (Ka) and peak concentration (Cma• of diltiazem (p<0.05, p<0.01). Area under the plasma concentration-time curve (AUC) of diltiazem in rats pretreated with morin were significantly higher than that in the control group (p<0.05, p<0.01), hence the absolute bioavailability (AB%) of diltiazem was significantly higher than that of the control group (p<0.05, p<0.01). Relative bioavailability (RB%) of diltiazem in rats pretreated with morin was increased by 1.36-to 2.03-fold. The terminal half-life (tl/2) and time to reach the peak concentration (Tin,x) of diltiazem were not altered significantly with morin pretreatment. AUC of desacetyldiltiazem was increased significantly (p<0.05) in rats pretreated with morin at doses of 7.5 and 15 mg/ kg, but metabolite-parent ratio (MR) of desacetyldiltiazem was decreased significantly (p<0.05), implying that pretreatment of morin could be effective to inhibit the CYP 3A4-mediated metabolism of diltiazem. There were no apparent changes of Tmax and h/2 of desacetyldiltiazem with morin pretreatment. Collectively, the pretreatment of morin significantly altered pharmacokinetics of diltiazem, which can be attributed to increased intestinal absorption as well as reduced first-pass metabolism. Based on these results, dose modification should be taken into consideration when diltiazem is used concomitantly with morin or morin-containing dietary supplements in clinical setting.
INTRODUCTION
Diltiazem is a calcium channel antagonist that is widely used in the treatment of angina, supraventricular arrhythmias and hypertension (Chaffman and Brogden, 1985; Pool, 1996; Weir, 1995) . Diltiazem undergoes an extensive presystemic metabolism (Buckley et al., 1990) , and the absolute bioavailability is approximately 40%, with a large inter individual variation. It was reported that in humans and dogs, N-demethyldiltiazem was the most abundant metabolite in plasma. In contrast, desacetyldiltiazem (DAD) and O-deacetyI-N-monodemethyl diltiazem were most predominant in the rabbits and rats, respectively Correspondence to: Jun-Shik Choi, College of Pharmacy, Chosun University, 375 Seosuk-Dong, Dong-Gu, Gwangju 501-759, Korea Tel: 82-62-530-6365, Fax: 82-62-222-5414 E-mail: jsachoi@chosun.ac.kr (Yeung et al., 1998) . CYP3A4 is the main human isoform of the N-demethylation of diltiazem in liver microsomes (Pichard et al., 1990) . CYP 3A4 is mainly located in the liver, but it is also found in the intestine (Watkins et al., 1987; Kolars et al., 1992) . It was reported that diltiazem is metabolized in small intestine (Lefebvre et al., 1996; Homsy et al., 1995a Homsy et al., , 1995b .
The reduced oral bioavailability of diltiazem might not only be due to the metabolizing enzyme CYP 3A4 but also to the P-glycoprotein (P-gp) efflux transporter in the small intestine. Yusa and Tsuruo (1989) reported that the calcium channel blockers verapamil, nicardipine, and diltiazem competitively inhibit the multi-drug resistance of P-gp. Saeki et al. (1993) reported that diltiazem is not only a multi-drug resistance (MDR) modulator but also a substrate for the efflux of P-gp. In vitro study using rat intestine suggested that diltiazem is a P-gp substrate (Molden et al., 2000b) . In the small intestine, P-gp is co-localized at the apical membrane of the epithelial cells with CYP 3A4 (Gottesman and Pastan, 1993) . Wacher et al. (2001) reported that diltiazem is both CYP 3A4 and Pgp substrate. P-gp and CYP3A4 might act synergistically to the presystemic drug metabolism by circulating the substrates of P-gp between the lumen and epithelial Cells, leading to prolonged exposure to CYP 3A4, resulting in a reduced absorption of the drug.
Flavonoids are the most abundant polyphenolic compounds present in fluits, vegetables, and plantderived beverages such as grape-fruit juice, tea, and red wine (Dixon et al., 1999) .
Among flavonoids, morin (3,5,7,2',4'-pentahydroxyflavone) is found in the fig and other Moraceae that are used as herbal medicines and exhibits various biological activities including antioxidation (Hanasaki et al., 1994; Kok et al., 2000 and Ramanathan et al., 1994) , anti-mutagenesis (Bhattacharya and Firozi, 1988; Francis et al., 1989) and anti-inflammation (Kim et al., 1999; Raso et al., 2001; Fang et al., 2003) . Furthermore, morin inhibits P-gp mediated cellular efflux of various agents (Zhang and Morris, 2003) . Previous studies have reported that morin could modulate the activities of the metabolic enzymes including cytochrome p-450 (CYPs, Hodek at al., 2002). In human liver microsomes, the formation of paclitaxel metabolite, 6o~-hydroxypaclitaxel (formed by CYP2C8), C3'-hydroxypaclitaxel, and C2-hydroxypaclitaxel (formed by CYP3A4) were inhibited by morin, the formation of 6o~-hydroxypaclitaxel was generally more inhibited than that of C3 '-hydroxypaclitaxel (Vaclavikova et al., 2003) . Panc-1 is a human pancreatic adenocarcinoma cell line, which expresses multidrug resistance-associated protein1 (MRP1), and morin significantly increased the accumulation of both daunomycin and vinblastine in Panc-1 cells (Nguyen et al., 2003) . So, it seems that morin might acts as dual inhibitors of CYP 3A4, P-gp, and MRP1 to modulate pharmacokinetic behavior of many drugs.
The pharmacokinetics of oral diltiazem is mainly affected by CYP 3A4 and P-gp at the first-pass metabolism. Morin, as a dual inhibitor of CYP 3A4 and P-gp, might influence the pharmacokinetics of diltiazem. Therefore, the purpose of this study was to investigate the effect of morin, a flavonoid, on the pharmacokinetics of diltiazem and one of its metabolites, desacetyldiltiazem in rats.
MATERIALS AND METHODS

Meterials
Diltiazem hydrochloride, desacetyldiltiazem, imipramine hydrochloride, and morin hydrate (3,5,7,2',4'-pentahydroxyflavone) was purchased from the Sigma Chemical Co. (St. Louis, MO, U.S.A.). Saline (0.9% NaCI injectable solution) was obtained from Choongwae Co. (Seoul, Korea). Acetonitrile, methanol, tert-butylmethyl ether were acquired from Merck Co. (Darmstadt, Germany). All other chemicals in this study were of reagent grade and used without further purification. The apparatus used in this study were a high performance liquid chromatograph (LC-10AD liquid chromatograph pump, SIL-10A autoinjector, SPD-10A UV-Vis detector, CBM-10A communications bus module, Shimadzu, Kyoto, Japan), a microcentrifuge (National Labnet, U.S.A.) and a sonicator (Daihan Co., Korea).
Animal studies
Male Sprague-Dawley rats (270-300 g) were purchased from Dae Han Laboratory Animal Research and Co. (Choongbuk, Korea), and had free access to normal standard chow diet (Jae II Chow, Korea) and tap water. Throughout the experiment, the animals were housed, four or five per cage, in laminar flow cages maintained at 22 + 2~ 50-60% relative humidity, under a 12 h lightdark cycle. The animals were kept under this condition for at least one week before the experiment. This experiment was carried out in accordance with the "Guiding Principles in the Use of Animals in Toxicology" adopted by the Society of Toxicology (U.S.A.) in July 1989 and revised in March 1999. The animal care committee in our institution (Chosun University) approved the present protocol.
Rats were divided in five groups of six each: a control group, given an oral single dose of diltiazem 15 mg/kg; three pretreated group, pretreated orally with morin (1.5 mg/kg, 7.5 mg/kg or 15 mg/kg) 30 min prior to diltiazem administration; i.v. group, injected 5 mg/kg of diltiazem through the femoral vein within 0.5 min.
Oral diltiazem solution was prepared by adding diltiazem (15 mg/kg) to distilled water (1.2 mL). Morin solution was prepared by adding morin (1.5, 7.5, and 15 mg/kg) to distilled water (1.2 mL). The right femoral artery was cannulated with polyethylene tubing (PE-50, Intramedic, Clay Adams, N J, U.S.A.) for blood sampling. Blood samples (0.6 mL) were withdrawn from the femoral artery at 0. 1, 0.25, 0.5, 1, 2, 3, 4, 8, 12 , and 24 h after the administration of diltiazem, and centrifuged at 5,000 rpm for 5 min to gain plasma samples (0.2 mL). The plasma samples were stored at -40~ until the HPLC analysis.
HPLC Assay
The plasma concentrations of diltiazem were determined by an HPLC assay by modification of the method reported by Goebel and Kolle (1985) . Briefly, 50 pL of imipramine (2 pg/mL), as the internal standard, and 1.2 mL of tertbutylmethyl ether were added to 0.2 mL of the plasma sample. It was then mixed for 2 min using a vortex-mixer and centrifuged at 13,000 rpm for 10 min. One mL of the organic layer were transferred to another clean test tube,
